The Role of Next Generation Sequencing Panels in Personalized Medicine of Lung Cancer: A Review Study

Lung cancer remains a leading cause of cancer-related deaths globally, with high mortality rates due to late-stage diagnosis. Early detection is crucial but challenging due to the asymptomatic nature of early-stage disease. Next-generation sequencing (NGS) has revolutionized oncology by enabling comprehensive genomic profiling, which can identify various genetic alterations from small samples. This review highlights the role of NGS panels in early lung cancer detection within personalized medicine. NGS allows the identification of actionable biomarkers, facilitating precision therapy and improving patient outcomes. Its efficiency in analyzing multiple genes simultaneously makes it a valuable tool for identifying therapeutic targets and resistance mechanisms. NGS is also cost-effective, reducing the need for multiple diagnostic tests, and its rapid data processing capabilities have led to increased adoption in clinical practice. As personalized approaches to cancer treatment gain traction, NGS is expected to play a key role in early diagnosis, prognosis, and monitoring of lung cancer. The ongoing development of advanced NGS panels and bioinformatics tools will enhance its clinical utility, positioning NGS as a cornerstone technology in lung cancer management.